Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Cytokinetics (CYTK) over the last 17 years, with Sep 2025 value amounting to -$116.9 million.

  • Cytokinetics' Free Cash Flow fell 14.34% to -$116.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.4 million, marking a year-over-year decrease of 11.39%. This contributed to the annual value of -$399.8 million for FY2024, which is 3.83% up from last year.
  • Cytokinetics' Free Cash Flow amounted to -$116.9 million in Q3 2025, which was up 11.76% from -$132.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Free Cash Flow peaked at -$28.6 million during Q1 2022, and registered a low of -$137.3 million during Q1 2025.
  • Over the past 3 years, Cytokinetics' median Free Cash Flow value was -$116.9 million (recorded in 2025), while the average stood at -$109.3 million.
  • In the last 5 years, Cytokinetics' Free Cash Flow crashed by 562.59% in 2021 and then grew by 26.91% in 2023.
  • Quarterly analysis of 5 years shows Cytokinetics' Free Cash Flow stood at -$62.5 million in 2021, then plummeted by 62.26% to -$101.4 million in 2022, then grew by 26.91% to -$74.1 million in 2023, then climbed by 9.77% to -$66.9 million in 2024, then dropped by 14.34% to -$116.9 million in 2025.
  • Its Free Cash Flow stands at -$116.9 million for Q3 2025, versus -$132.4 million for Q2 2025 and -$137.3 million for Q1 2025.